BIOLASE (NASDAQ:BIOL) Lifted to “Hold” at StockNews.com

StockNews.com upgraded shares of BIOLASE (NASDAQ:BIOLFree Report) from a sell rating to a hold rating in a research note released on Tuesday morning.

BIOLASE Stock Performance

Shares of NASDAQ:BIOL opened at $0.42 on Tuesday. The company has a quick ratio of 0.71, a current ratio of 1.40 and a debt-to-equity ratio of 34.06. The firm has a market cap of $1.45 million, a PE ratio of 0.00 and a beta of 0.86. The company’s 50 day moving average price is $1.02 and its two-hundred day moving average price is $6.99. BIOLASE has a 12-month low of $0.35 and a 12-month high of $54.01.

BIOLASE (NASDAQ:BIOLGet Free Report) last issued its earnings results on Thursday, November 9th. The medical technology company reported ($3.89) earnings per share for the quarter. BIOLASE had a negative net margin of 50.61% and a negative return on equity of 503.34%. The company had revenue of $10.92 million during the quarter.

Institutional Trading of BIOLASE

Hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its position in BIOLASE by 128.5% in the fourth quarter. Renaissance Technologies LLC now owns 43,059 shares of the medical technology company’s stock valued at $28,000 after buying an additional 24,211 shares in the last quarter. Acadian Asset Management LLC bought a new stake in shares of BIOLASE in the second quarter worth $67,000. Walleye Capital LLC bought a new stake in shares of BIOLASE in the second quarter worth $100,000. Citadel Advisors LLC bought a new stake in shares of BIOLASE in the second quarter worth $118,000. Finally, State Street Corp grew its stake in shares of BIOLASE by 4.5% in the first quarter. State Street Corp now owns 436,076 shares of the medical technology company’s stock worth $154,000 after purchasing an additional 18,682 shares during the last quarter.

About BIOLASE

(Get Free Report)

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.

Featured Stories

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.